ALC 📈 Alcon - Overview
Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0432492467
ALC: Contact Lenses, Surgical Instruments, Implantables, Vitamins, Eye Drops
Alcon AG is a global medical company that specializes in the development, manufacturing, and distribution of eye care products, catering to the needs of eye care professionals and their patients worldwide. The company operates through two primary segments: Surgical and Vision Care. The Surgical segment offers an extensive range of products, including equipment, instrumentation, and diagnostics for surgical procedures, as well as intraocular lenses and other implantables. This segment also provides consumables such as viscoelastics, surgical solutions, and incisional instruments, which are essential for various surgical procedures.
Within the Surgical segment, Alcon AG offers a variety of cataract products, including the Centurion vision system, LenSx laser system, and ARGOS biometer, which are designed to enhance the precision and efficiency of cataract surgeries. Additionally, the company provides custom pak surgical procedure packs, vitreoretinal products, and refractive surgery products, such as WaveLight lasers and Contoura Vision, which are used for LASIK treatment. The company also offers implantable products, including AcrySof IQ products, which are designed to correct presbyopia and astigmatism during cataract surgery. Other notable products in this segment include the EX-PRESS glaucoma filtration device and the ORA system for intra-operative measurements.
The Vision Care segment of Alcon AG focuses on providing a range of products for the care and maintenance of vision, including daily disposable, reusable, and color-enhancing contact lenses. The company also offers ocular health products, such as dry eye treatments, glaucoma medications, and contact lens care solutions, as well as ocular vitamins and redness relievers. These products are designed to promote eye health and provide relief from various ocular conditions, ultimately enhancing the quality of life for individuals with vision impairments.
With a rich history dating back to 1945, Alcon AG has established itself as a leading player in the eye care industry, with a strong presence in the global market. The company, formerly known as Alcon Universal S.A., changed its name to Alcon Inc. in December 2001 and is currently headquartered in Geneva, Switzerland. As a publicly traded company listed on the NYSE under the ticker symbol ALC, Alcon AG is committed to delivering innovative eye care solutions that meet the evolving needs of eye care professionals and their patients worldwide.
Additional Sources for ALC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ALC Stock Overview
Market Cap in USD | 43,093m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2019-04-09 |
ALC Stock Ratings
Growth 5y | 53.9% |
Fundamental | 47.6% |
Dividend | 45.6% |
Rel. Strength Industry | 168 |
Analysts | 4.37/5 |
Fair Price Momentum | 76.90 USD |
Fair Price DCF | 56.56 USD |
ALC Dividends
Dividend Yield 12m | 0.31% |
Yield on Cost 5y | 0.47% |
Annual Growth 5y | 3.97% |
Payout Consistency | 99.4% |
ALC Growth Ratios
Growth Correlation 3m | -93% |
Growth Correlation 12m | 70.8% |
Growth Correlation 5y | 75.5% |
CAGR 5y | 8.42% |
CAGR/Mean DD 5y | 0.80 |
Sharpe Ratio 12m | 0.34 |
Alpha | -13.14 |
Beta | 0.88 |
Volatility | 24.17% |
Current Volume | 917.6k |
Average Volume 20d | 839.5k |
As of December 21, 2024, the stock is trading at USD 84.76 with a total of 917,602 shares traded.
Over the past week, the price has changed by +0.70%, over one month by -0.87%, over three months by -13.05% and over the past year by +13.78%.
Partly, yes. Based on ValueRay Fundamental Analyses, Alcon (NYSE:ALC) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.60 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALC as of December 2024 is 76.90. This means that ALC is currently overvalued and has a potential downside of -9.27%.
Alcon has received a consensus analysts rating of 4.37. Therefor, it is recommend to buy ALC.
- Strong Buy: 16
- Buy: 6
- Hold: 4
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, ALC Alcon will be worth about 84.7 in December 2025. The stock is currently trading at 84.76. This means that the stock has a potential downside of -0.07%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 100.2 | 18.2% |
Analysts Target Price | 93.3 | 10.1% |
ValueRay Target Price | 84.7 | -0.1% |